血液系统恶性肿瘤中CAR-T细胞治疗相关凝血异常:综述
本综述汇总接受CAR-T细胞输注的复发/难治性血液系统恶性肿瘤患者凝血异常的临床表现、凝血参数、发病机制、危险因素及其对疗效的影响,旨在提高临床关注并提升CAR-T治疗安全性;因数据有限,结论可能随经验积累而变化。
要点
- CAR-T细胞治疗相关凝血异常可从凝血参数轻度异常到严重出血或弥散性血管内凝血。
- 凝血异常可伴威胁生命的多器官功能障碍,是CAR-T治疗的常见并发症。
- 综述涵盖凝血异常的临床表现、凝血参数、发病机制、危险因素及对疗效的影响。
核心结论
- 综述呈现了接受CAR-T细胞输注患者凝血异常的临床特征、凝血参数、发病机制、危险因素及其对疗效的影响。
- 因数据有限,这些结论可能随更多经验积累而发生变化。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 凝血异常是CAR-T细胞治疗的常见并发症,严重程度从凝血参数单纯异常到严重出血或弥散性血管内凝血不等。
- 严重凝血异常可与威胁生命的多器官功能障碍相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因数据有限,这些结论可能随更多经验积累而发生变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR)-T-cell therapy has demonstrated considerable efficacy and safety in the treatment of patients with relapsed/refractory haematological malignancies. Owing to significant advances, CAR-T-cell therapeutic modality has undergone substantial shifts in its clinical application. Coagulation abnormalities, which are prevalent complications in CAR-T-cell therapy, can range in severity from simple abnormalities in coagulation parameters to serious haemorrhage or disseminated intravascular coagulation associated with life-threatening multiorgan dysfunction. Nonetheless, there is a lack of a comprehensive overview concerning the coagulation abnormalities associated with CAR-T-cell therapy. With an aim to attract heightened clinical focus and to enhance the safety of CAR-T-cell therapy, this review presents the characteristics of the coagulation abnormalities associated with CAR-T-cell therapy, including clinical manifestations, coagulation parameters, pathogenesis, risk factors and their influence on treatment efficacy in patients receiving CAR-T-cell infusion. Due to limited data, these conclusions may undergo changes as more experience accumulates.
引用
- Peng X, Zhang X, Zhao M, et al. Coagulation abnormalities associated with CAR-T-cell therapy in haematological malignancies: A review. Br J Haematol. 2024. PMID: 38887101. doi:10.1111/bjh.19583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。